ArticleDrug and alcohol dependence2026
Opioid use disorder and medication for opioid use disorder among pregnant women with commercial insurance in the United States, 2016-2020.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Perinatal Mental Health Detection and Prediction Using Mobile Sensing Data: Systematic Review.JMIR mental health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo examine the prevalence of opioid use disorder (OUD) diagnosis and medications for OUD (MOUD), which includes methadone, buprenorphine, and naltrexone, during pregnancy, and examine pre-pregnancy clinical factors associated with MOUD receipt in a nationwide commercial insurance database. STUDY
designWe utilized data from Marketscan to identify pregnancies among women aged 15-54 years from 2016 to 2020. Individuals were included if they had consecutive enrollment from 90 days before the estimated last menstrual period (LMP) through 90 days postpartum. OUD and MOUD were identified using International Classification of Diseases (ICD) codes and pharmaceutical claims or Healthcare Common Procedure Coding System (HCPCS) codes. Multivariable Poisson regression was used to examine demographic and pre-pregnancy clinical factors associated with MOUD.
resultsWe identified 909,241 total pregnancies, among which 2926 (0.3%) individuals had an OUD diagnosis during pregnancy or postpartum. Among women diagnosed pre- or during pregnancy with OUD (n = 2346), 1014 (40.2%) received MOUD. Demographic and clinical factors positively associated with an OUD diagnosis included younger age and non-metropolitan statistical area (MSA) residence. Factors negatively associated with MOUD receipt during pregnancy included co-occurring chronic pain or concurrent substance use disorder diagnosis other than OUD. Having two or more mental health disorders was positively associated with MOUD receipt.
conclusionLess than half of pregnant women with OUD received MOUD, the gold standard for treatment. Our results demonstrate substantial missed opportunities for MOUD treatment during pregnancy, highlighting the need for targeted interventions to improve evidence-based perinatal OUD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.